Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 2Resectable Pancreatic Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 304Carboplatin 157Nivolumab 154Cisplatin 140Cyclophosphamide 131Paclitaxel 127Magnetic Resonance Spectroscopy 99Specimen Handling 96Radiotherapy 91Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 76Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61Radiation 60durvalumab 60Lenalidomide 59Pemetrexed 59Taxes 57Prednisone 55Bevacizumab 54fludarabine 54olaparib 53Vincristine 50Cytarabine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × paricalcitol × 1 year × Clear all
NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed
34 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

HonorHealth Research Institute

Phase 2 Completed
40 enrolled 22 charts
Gastrointestinal

Resectable Pancreatic Cancer

NCT04524702 2026-01-23

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Emory University

Phase 2 Completed
10 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡